M&A Deal Summary

Mubadala Capital Acquires NOVA Chemicals

On January 1, 2017, sovereign wealth fund Mubadala Capital acquired chemicals company NOVA Chemicals

Acquisition Highlights
  • This is Mubadala Capital’s 1st transaction in the Chemicals sector.
  • This is Mubadala Capital’s 1st transaction in Canada.
  • This is Mubadala Capital’s 1st transaction in Alberta.

M&A Deal Summary
Date 2017-01-01
Target NOVA Chemicals
Sector Chemicals
Buyer(s) Mubadala Capital
Deal Type Buyout (LBO, MBO, MBI)

Target

NOVA Chemicals

Calgary, Alberta, Canada
NOVA Chemicals develops and manufactures chemicals and plastic resins that make everyday life healthier, easier and safer. Our employees work to ensure health, safety, security, and environmental stewardship through our commitment to sustainability and responsible care. NOVA Chemicals was founded in 1954 and is based in Calgary, Alberta.

Search 201,839 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mubadala Capital

Investor

Category Sovereign Wealth Fund
Founded 2002
PE ASSETS 276.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Mubadala Capital is a private equity firm focused on investing capital across a range of assets worldwide. The Firm primarily invests in private and public assets, but also considers credit, real estate, and alternatives. Mubadala invests in a variety of sectors including industrials, healthcare, energy, renewables, financial services, infrastructure, and business services. Mubadala Capital was founded in 2008 and is headquartered in Abu Dhabi, United Arab Emirates.

DEAL STATS #
Overall 5 of 43
Sector (Chemicals) 1 of 2
Type (Buyout (LBO, MBO, MBI)) 3 of 8
State (Alberta) 1 of 2
Country (Canada) 1 of 3
Year (2017) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-06 Envision Pharma

Horsham, United Kingdom

Envision Pharma is a global technology and scientific communication company serving the pharmaceutical, biotechnology, and medical device companies. Envision has grown steadily under consistent leadership across its three core business areas that include scientific solutions – strategic publication planning and related data dissemination services, technology Solutions – design, development, implementation, and support of innovative and strategic management software for life sciences clients including publication planning and management (DatavisionTM), clearance approval (dvClear), and activity request management (Visiontracker) and professional consulting solutions policy, process, compliance and guideline consultancy to life-science companies. Envision Pharma was founded in 2001 and is based in Horsham, United Kingdom.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-22 CityFibre

London, United Kingdom

CityFibre builds, designs and operates pure-fibre networks across the UK. As the UK’s only nationwide, wholesale provider of dark fibre, and with a range of active products, CityFibre serves tier 1 providers, local authorities, mobile operators and communications providers. CityFibre was founded in 2011 and is based in London, United Kingdom.

Buy £538M
Mergr

Product

Company

Legal